‘We cannot risk further delays’

Federal Government accused of “failing to commit” to a national RSV immunisation program after rejections to fund two vaccines, and protracted negotiations over a third The PBAC has rejected funding applications for two RSV vaccines—nirsevimab (Beyfortus) for infants and Arexvy for seniors—based on cost-effectiveness concerns. And while it has recommended listing of RSV vaccine Abrysvo